The U.S. Federal Trade Commission is looking into how big pharmacy benefit managers like CVS Caremark affect pricing and patients’ access to prescription drugs at a time when costs of some medicines, even older ones like insulin, have skyrocketed, the agency said Tuesday. As part of the probe, the FTC is sending demands for information…